Marimed (MRMD) Q3 2025 earnings summary

Executive summary

• Achieved sequential growth in wholesale and retail revenue, with adjusted EBITDA and positive cash flow from operations also increasing.

• Expanded brand distribution to Maine, Pennsylvania, and New York through new agreements, supporting the 'Expand the Brand' growth strategy.

• Completed acquisition of First State Compassion Center in Delaware and finalized two dispensary acquisitions in Illinois and Maryland in 2024.

• Maintained significant brand share in core markets despite industry challenges such as price pressure and retail oversaturation.

• Exited the Missouri market to focus on more profitable opportunities, with minimal financial impact expected.

Financial highlights

• Q3 2025 consolidated revenue was $40.8M, up 0.4% year-over-year and 3% sequentially; nine-month revenue was $118.2M, down 0.5% from prior year.

• Wholesale revenue grew to $18.0M in Q3 2025 from $16.3M in Q3 2024; retail revenue declined to $22.6M from $23.4M.

• Adjusted EBITDA for Q3 2025 was $5.1M (12.6% margin), up from $4.7M (11.5% margin) in Q3 2024.

• GAAP net loss was $2.9M for Q3 2025, compared to $1.0M in Q3 2024; nine-month net loss was $9.9M.

• Cash and cash equivalents at September 30, 2025: $6.6M, down from $7.3M at year-end 2024.

Outlook and guidance

• Management expects current cash and future funding to be sufficient for at least the next twelve months, with disciplined capital allocation and continued expansion.

• Anticipates brand distribution in Pennsylvania and New York to begin in 2026, pending regulatory approval and facility build-outs.

• Expects continued topline growth from wholesale expansion and new product launches, including hemp-derived THC products.

• Margins anticipated to remain stable in Q4, with slight expansion expected in the new year as efficiencies are realized.